Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company,
announced that it has entered into an exclusive License Agreement with
Knight Therapeutics Inc. (TSX: GUD) that grants Knight the exclusive
right to commercialize NERLYNXA® (neratinib) in Canada.

Puma Biotechnology filed a new drug submission for NERLYNXA® with Health
Canada in July 2018 for the extended adjuvant treatment of adult
patients with early stage HER2-overexpressed/amplified breast cancer
following adjuvant trastuzumab-based therapy. Under the terms of the
License Agreement, Knight will be responsible for all commercial
activities and future regulatory submissions for NERLYNXA® in Canada.
Puma will receive upfront and milestone payments up to $7.2 million USD
throughout the term of this agreement, as well as double digit royalties
on net sales of NERLYNX in Canada.

"Our new agreement with Knight demonstrates our commitment to bringing
NERLYNX to patients around the world while continuing to focus our
commercial resources on the U.S. market,a?? stated Alan H. Auerbach, Chief
Executive Officer and President of Puma. "We are confident this new
partnership will help patients in Canada access NERLYNX at the earliest

"We are excited to partner with Puma to offer a new treatment option to
Canadian breast cancer patients," said Jonathan Ross Goodman, Chief
Executive Officer of Knight. "While adjuvant trastuzumab-based therapy
has been shown to reduce the risk of recurrence in early stage
HER2-positive breast cancer, up to 25% of patients treated with adjuvant
trastuzumab will have a recurrence. NERLYNXA® has been shown to
significantly reduce the risk of recurrence in those patients who were
previously treated with trastuzumab."
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Октябрь 2021    »